Clinical Trial Detail

NCT ID NCT02684292
Title Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin

Pembrolizumab

Age Groups: adult

No variant requirements are available.